Terevalefim API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Terevalefim API 1070881-42-3?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Terevalefim. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Terevalefim
- Synonyms:
- Refanalin , Terevalefim
- Cas Number:
- 1070881-42-3
- DrugBank number:
- DB16397
- Unique Ingredient Identifier:
- GG91UXK2M5
General Description:
Terevalefim, identified by CAS number 1070881-42-3, is a notable compound with significant therapeutic applications. Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).
Mechanism of Action:
Terevalefim functions by: Terevalefim, a small molecule developed by Angion Biomedica Corp, mimics the activity of hepatocyte growth factor (HGF). Through its actions, it activates the c-Met cascade, exhibits c-Met dependence and c-Met receptor activation. As it is able to activate repair pathways, it has been tested in clinical trials for acute kidney injury and in delayed graft function. As of July 2020, Angion has announced a Phase 2 proof-of-concept trial to invesigate terevalefim on preventing and mitigating lung injury in patients with COVID-19 (NCT04459676). This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Categories:
Terevalefim is categorized under the following therapeutic classes: Sulfur Compounds. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
